Artikel
Increase in the safety margin by BGP-15 of cisplatin in the guinea pig
Suche in Medline nach
Autoren
Veröffentlicht: | 24. April 2006 |
---|
Gliederung
Text
Objectives: The aim of this study was to investigate the effect of the BGP-15 cisplatin-induced experimental neuropathy in a subacute treatment schedule in guinea pigs. Neuropathy was characterized by the changes of objective hearing threshold and interpeak latency. Study design: short communication.
Methods: The neuroprotective effect of BGP-15 against peripheral sensory neuropathy was studied in guinea pigs exposed to short-term cisplatin administration. Changes in ABR threshold and interpeak latencies were determind after short term treating the animals either cisplatin, cisplatin+BGP-15 and cisplatin+placebo.
Results: Electrophysiological recordings were carried out by stimulating the acoustic nerve. BGP-15 couldn't protect increase of hearing thresholds, but decreased the interpeak latency I.-V. on BERA.
Conclusions: Our in vivo studies have demonstrated that BGP-15 protected auditory neurons from the toxic effects of cisplatin. This chemoprotective potential of BGP-15 could be well correlated with its PARP-inhibitory effect and its ability to protect against the damages induced by the increased level of reactive oxygen species (ROS) in response to anti-cancer treatment.
Key words: toxic effects of antitumor drugs, peripheral sensory neuropathy, prevention of neuropathy, nerve conduction velocity, poly- (ADP-ribose)-polymerase (PARP) enzyme, modulation of PARP activity, BGP-15, cisplatin.